drugset / Trial / NCT04622345

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT04622345 ↗

Phase 2 Completed 47 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

Timeline

Start
2020-11-21
Primary completion
2021-05-22
Completion
2021-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject VSJ-110 Unknown — Other

Indications